CN109641027A - For improving the composition of the nerve ending as caused by anticarcinogen - Google Patents
For improving the composition of the nerve ending as caused by anticarcinogen Download PDFInfo
- Publication number
- CN109641027A CN109641027A CN201780050200.XA CN201780050200A CN109641027A CN 109641027 A CN109641027 A CN 109641027A CN 201780050200 A CN201780050200 A CN 201780050200A CN 109641027 A CN109641027 A CN 109641027A
- Authority
- CN
- China
- Prior art keywords
- composition
- protein
- fatty acid
- milk
- anticarcinogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/19—Dairy proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7016—Disaccharides, e.g. lactose, lactulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/20—Milk; Whey; Colostrum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
The present invention relates to the improvement composition for giving caused nerve ending by anticarcinogen, it includes: the milk protein hydrolysate as protein and the protein from acidified milk；As the medium chain fatty acid of lipid or its triglycerides and n-3 system fatty acid；And the isomaltoketose as carbohydrate.
Description
The reference of related application
Present patent application claims priority based on Japanese patent application 2016-161457 filed on August 19th, 2016
It weighs, the complete disclosure in the earlier patent application becomes disclosed a part of this specification by quoting.
Technical field
Now, the death toll as caused by cancer increases increasingly in the whole world, and the research of effective treatment method persistently carries out.
The treatment method of cancer substantially have operative treatment, chemotherapy, radiotherapy these three, as chemotherapy, used makes more
With the method for anticarcinogen.In recent years, in the treatment for having used anticarcinogen, platinum preparation (platinum preparation), catharanthus roseus have been used more
Alkaloid system preparation and Japanese yew (taxane) are preparation.
On the other hand, anticarcinogen as platinum preparation, vinca alkaloids system preparation and Japanese yew system preparation, as what is used
In the case of side effect, occur the nerve endings such as numbness in hands and feet, pain, cacesthesia (non-patent literature 1) sometimes.By resisting
Nerve ending caused by cancer medicine will take a long time and could restore after the use for stopping anticarcinogen sometimes, appetite
Also substantially decline, the quality of life (QOL) of patient may be made to significantly reduce.Further, there is the case where nerve ending
Under, its is intensification in order to prevent, it has to which the case where administered dose or suspension for reducing anticarcinogen are given is more, as caused by anticarcinogen
Nerve ending is considered as significant problem (non-patent literature 2) in terms for the treatment of cancer.In particular, effective in anticancer drug therapy
In the case where, as postoperative complementary therapy carry out in the case where, it is expected that continuing while controlling the symptom of nerve ending
It treats (non-patent literature 1).Therefore, in order to continue anticancer drug therapy, the establishment of the ameliorative way of nerve ending is extremely
Important project.In addition, also requiring the nutritional status for maintaining the patient of appetite stimulator during anticancer drug therapy.However, status
It is that still there is no effective methods.
The method that is intensification and attempting of nerve ending substantially divides into two kinds in order to prevent under such status
(non-patent literature 2).One is by reduce anticarcinogen administered dose or suspension give, extends drug withdrawal during prevent tip mind
Through the intensification method of obstacle.It is the unique reliable method for restraining nerve ending that anticarcinogen is given in suspension, but sometimes
Persistently or more deteriorate even if nerve ending after stopping to give.Another kind be by with prevention nerve ending
Breaking-out, carry out medicinal treatment and use, Heal Thyself practice, make nerve ending mitigate method (non-patent literature
2).In medicinal treatment for mitigating nerve ending, antidepressants (Amitriptyline Hydrochloride), antiepileptic have often been used
(carbamazepine), antiarrhymic (mexiletine), electrolytes (magnesium, calcium) vein give, Vitamin B12 preparation (first cobalt
Amine), amino acids (acetyl L-carnitine), Chinese medicine ox cart shenqi pill (Goshajinkigan) etc. (non-patent literature 1 and 2).So
And these medicinal treatments are only empirically to attempt ease symptom, effect is limited.In addition, controlling in nerve ending
In treatment, the use of drug as described above is commonly considered as insurance and is applicable in outer use, from the viewpoint of mitigating burden of patients,
It is preferred that drug is inhibited to use.
Existing technical literature
Non-patent literature
Non-patent literature 1: great Shi is third, and will is cured in Fukuoka, 104 (5), 171-180, and 2013
Non-patent literature 2: waste river and a man of virtue and ability etc., the medical Yao miscellany will of Japan's mitigation, 4,1-13,2011
Summary of the invention
The present invention this time has been found that the patient for making to be given anticarcinogen absorbs specific composition, then giving by anticarcinogen
Caused nerve ending is given to effectively improve.It has furthermore been found that by using above-mentioned composition, it can be in nerve ending
While obstacle improves, the nutrition supply to the patient in anticancer drug therapy is effectively performed.The present invention is based on the recognition that.
Therefore, the present invention is made with providing to effectively improve by the means for giving caused nerve ending of anticarcinogen
For its purpose.In addition, the present invention is while nerve ending improves, to be effectively performed the trouble in the treatment to anticarcinogen
The nutrition supply of person is as its purpose.
According to the present invention, following invention is provided.
(1) a kind of composition gives caused nerve ending by anticarcinogen for improving, it includes: as
The milk protein hydrolysate of protein component and protein from acidified milk；As the medium chain fatty acid of fat constituent or its
Triglycerides and n-3 system fatty acid；And the isomaltoketose as carbohydrate content.
(2) composition according to (1), above-mentioned lactoprotein be selected from casein, lactoprotein concentrate (MPC),
In whey protein concentrate (WPC), whey protein sepd (WPI), α-lactalbumin, beta lactoglobulin and lactoferrin
It is at least one kind of.
(3) composition according to (1) or (2), above-mentioned milk protein hydrolysate are serum protein hydrolysate.
(4) composition according to any one of (1)~(3), the content of above-mentioned milk protein hydrolysate is every
100kcal composition is 0.5~3.0g.
(5) composition according to any one of (1)~(4), the above-mentioned protein source from acidified milk is in new
Fresh cheese.
(6) composition according to any one of (1)~(5), the above-mentioned protein source from acidified milk is in making
With lactobacillus bulgaricus (Lactobacillus bulgaricus), streptococcus thermophilus (Streptococcus thermophilus) or their combination make acidified milk obtained by skim-milk fermentation.
(7) composition according to any one of (1)~(6), the content of the above-mentioned protein from acidified milk are
Every 100kcal composition is 0.5~6g.
(8) composition according to any one of (1)~(7), above-mentioned medium chain fatty acid are in carbon atom number 8~14
Chain fatty acid.
(9) composition according to any one of (1)~(8), the content of above-mentioned medium chain fatty acid or its triglycerides
Be every 100kcal composition be 0.01~2g.
(10) composition according to any one of (1)~(9), above-mentioned n-3 system fatty acid include to be selected from 22 carbon
One or more of acid and eicosapentaenoic acid fatty acid.
(11) composition according to any one of (1)~(10), the content of above-mentioned n-3 system fatty acid is every
100kcal composition is 0.05~2.2g.
(12) composition according to any one of (1)~(11), the content of above-mentioned isomaltoketose are every 100kcal
Composition is 1~15g.
(13) composition according to any one of (1)~(12), further comprises as the n-6 system of lipid components
The weight ratio of fatty acid, the n-6 system fatty acid and n-3 system fatty acid is 1~3.
(14) composition according to any one of (1)~(13), further includes selected from dietary fiber, vitamin
At least one kind of ingredient in ingredient and mineral composition.
(15) composition according to any one of (1)~(14), is beverage.
(16) a kind of method is the method for giving caused nerve ending improved by anticarcinogen, it includes under
State step: make to need to be improved absorbed by the object for giving caused nerve ending of anticarcinogen it is a effective amount of of the invention
Composition.
(17) composition is for improving by the manufacture of the composition for giving caused nerve ending of anticarcinogen
In application, above-mentioned composition includes: the milk protein hydrolysate as protein component and the protein from acidified milk；
As the medium chain fatty acid of fat constituent or its triglycerides and n-3 system fatty acid；And the different malt ketone as carbohydrate content
Sugar.
Caused nerve ending is given by anticarcinogen according to the present invention it is possible to improve significantly.Further, root
According to the present invention, the nutrient to patient can be effectively performed while nerve ending improves.According to such sheet
Invention can continue anticancer drug therapy while making QOL maintain, improve in the patient for receiving anticancer drug therapy.
Detailed description of the invention
Fig. 1 is the nerve ending in the cancer patient (1) for indicating to take in the anticancer drug therapy of composition of the invention
The figure of the variation of the adverse events Grade of obstacle.
Fig. 2 is the tip in the other cancer patients (1) for indicating to take in the anticancer drug therapy of composition of the invention
The figure of the variation of the adverse events Grade of neurological disorder.
Specific embodiment
Composition of the invention includes: the milk protein hydrolysate as protein component and the albumen from acidified milk
Matter；As the medium chain fatty acid of fat constituent or its triglycerides and n-3 system fatty acid；And the different malt as carbohydrate content
Ketose.If mentioned component is engaged in composition, may be implemented to give caused nerve ending to by anticarcinogen
The excellent improvement of obstacle is the unexpected fact.
Protein component
Protein component of the invention includes milk protein hydrolysate and the protein from acidified milk.
As lactoprotein of the invention, as long as not interfering effect of the invention, there is no particular limitation, junket egg can be enumerated
White, lactoprotein concentrate (Milk Protein Concentrate:MPC, also referred to as total milk protein matter (Total Milk
Protein:TMP)), the whey proteins, whey protein such as whey, α-lactalbumin (α-La) and beta lactoglobulin (β-Lg)
Concentrate (Whey Protein Concentrate:WPC), whey protein sepd (Whey Protein Isolate:
) and lactoferrin etc. WPI.The hydrolysate of these lactoproteins, which also can according to need, the amino acid residue such as modifies,
To change the physical characteristics such as dissolubility, viscosity, gelation, thermal stability, emulsion stability, physiology characteristic.In addition, this hair
Milk protein hydrolysate in bright, which also can according to need, to be separated into regulation molecular weight or less and uses.It is hydrolyzed as lactoprotein
The molecular weight of object, preferably 50,000 hereinafter, more preferably 30, and 000 hereinafter, further preferably 10, and 000 or less.
As milk protein hydrolysate of the invention, use for example, above-mentioned each lactoprotein is hydrolyzed by enzyme
Obtained by substance.As the enzyme for hydrolyzing lactoprotein, as long as not interfering effect of the invention, there is no particular limitation, can be with
Use the various protease of endo protease and exoproteinase, the object and comprising these of being roughly refined comprising these protease
Bacterial cell disruption object of protease etc..They also may be used alone, can also be used in combination a variety of.It, can as various protease
Enumerate for example, pepsin, trypsase, chymotrypsin and the pancreatin of the protease as animal origin, as plant
Papain, bromelain and Chinese grooseberry protease, the microbe-derived protease of the protease in source.These albumen
Commercially available product can be used in enzyme.As commercially available endo protease, can enumerate for example, be all sold by Novozymes society, lichens
ア Le カ ラ ー ゼ (registered trademark), the bacillus lentus in the source bacillus (Bacillus licheniformus)
The ニ ュ ー ト ラ ー ゼ (registration of the エ ス ペ ラ ー ゼ (registered trademark), withered grass bacterium source in the source (Bacillus lentus)
Trade mark) and the source bacillus amyloliquefaciens (Bacillus amyloliquefaciens) プ ロ タ メ ッ Network ス (registrar
Mark) and the trypsase (PTN (registered trademark)) in pig pancreas source etc..In addition, example can be enumerated as commercially available exoproteinase
Such as, the フ レ ー バ ー ザ イ system (registered trademark) in the source aspergillus oryzae (Aspergillus oryzae) and pig or ox internal organ come
The carboxypeptidase etc. in source.In the case where hydrolyzing lactoprotein of the invention, bacillus licheniformis source is preferably applied in combination
The trypsase (PTN) of ア Le カ ラ ー ゼ and pig pancreas source.
An embodiment as milk protein hydrolysate of the invention, whey protein hydrolysate can for example lead to
Cross following methods modulation.
By the whey protein sepd (WPI) of the protein comprising about 90 weight % of dry weight to include 8 weight %
The mode of protein be dissolved in water.Resulting WPI aqueous solution is heated 2 minutes at 85 DEG C makes whey protein denaturation.?
Bacillus licheniformis is added in a manner of becoming 2 weight % relative to the weight of whey protein in aqueous solution after denaturation treatment
The ア Le カ ラ ー ゼ 2.4L in source, reacts 3 hours at 55 DEG C.Then, further with the weight relative to whey protein
Mode as 3 weight % adds the trypsase (PTN6.0S) in pig pancreas source, reacts 3 hours at 55 DEG C.It will be resulting
Reaction solution is with 20, and 000 × g is centrifugated 10 minutes, and the ultrafiltration membrane by supernatant for molecular cut off 10,000 will pass through
The grade of ultrafiltration membrane is divided into the hydrolysate of whey protein.
Commercially available product can be used in milk protein hydrolysate of the invention.As commercially available milk protein hydrolysate, can enumerate
For example, Peptigen IF-3080, Peptigen IF-3090, PeptigenIF-3091 and Lacprodan DI-3065 are (
Aria Foods Ingredients society system), WE80BG (FrieslandCampina Domo society system), Hyprol 3301,
Hyprol 8361 and Hyprol 8034 (being all Kerry society system), Tatua2016 and HMP406 (being all Tatua society system), Whey
Hydrolysate 7050 (Fonterra society system) and Biozate3 (Davisco society system) etc..
The content of milk protein hydrolysate in composition of the invention can be according to the contents of other ingredients, composition
Morbid state, symptom, age, weight, the purposes etc. for giving object carry out appropriate adjustment.Specifically, about in composition of the invention
Milk protein hydrolysate content, as long as not interfering effect of the invention, there is no particular limitation, every 100kcal composition
For 0.5~3.0g, preferably 0.9~3.0g, more preferably 1.2~2.0g.
As the protein from acidified milk of the invention, the protein that acidified milk is included can be used.As hair
Kefir milk can be enumerated for example, by domestic animals creams, the skimmed milk of these domestic animals cream, portion such as cow's milk, buffalo's milk, goat dairy, sheep cream and horse creams
Divide skimmed milk, reduction rich milk, reduction skimmed milk, reduction partly skimmed milk and the butter and milk manufactured by these domestic animal creams
The liquid fermentation dairy milk starting material of the fermentation one kind or two or more hybrid modulation of dairy milk starting material such as oil passes through the bacteriums such as lactic acid bacteria, Bifidobacterium hair
Acidified milk obtained by ferment.As the used lactic acid bacteria, Bifidobacterium of fermenting, can enumerate for example, lactobacillus bulgaricus
(Lactobacillus bulgaricus), streptococcus thermophilus (Streptococcus thermophilus), streptococcus lactis
(Streptococcus lactis), streptococcus cremoris (Streptococcus cremoris), biacetyl streptococcus lactis
(Streptococcus diacetilactis), enterococcus faecium (Enterococcus faecium), enterococcus faecalis
(Enterococcus fecalis), milk Lactobacillus paracasei (Lactobacillus casei), Lactobacillus helveticus
(Lactobacillus helveticus), lactobacillus acidophilus (Lactobacillus acidophilus), Lactobacillus rhamnosus
(Lactobacillus rhamnosus), lactobacillus plantarum (Lactobacillus plantarum), Lactobacillus murinus
(Lactobacillus murinus), lactobacillus reuteri (Lactobacillus reuteri), Lactobacillus brevis
(Lactobacillus brevis), Lactobacillus gasseri (Lactobacillus gasseri), bifidobacterium longum
(Bifidobacterium longum), bifidobacterium bifidum (Bifidobacterium bifidum), bifidobacterium bifidum
(Bifidobacterium bifidum), bifidobacterium breve (Bifidobacterium breve) etc..In addition, fermenting in manufacture
When newborn, other than above-mentioned lactic acid bacteria, Bifidobacterium, the thin of Propionibacterium (Propionibacterium) category also can be used together
Bacterium.
As acidified milk used in the present invention, can enumerate for example, Yoghourt, cheese etc..As cheese, do not make it preferably
The fresh cheese of curing can be enumerated as fresh cheese for example, farmers' (cottage), quark (quark), fibril
(string), Saudi Arabia blue (neufchatel), cream cheese (Cream cheese), horse Soviet Union lira (mozzarella), inner is received
Section's tower (Ricotta) and Maas card friend (Mascarpone) etc..
About the protein from acidified milk in the present invention, as long as not interfering effect of the invention, so that it may to make
The protein modulated with any acidified milk, but preferably using quark or pass through lactobacillus bulgaricus (Lactobacillus
Bulgaricus) and streptococcus thermophilus (Streptococcus thermophilus) make skim-milk fermentation alone or in combination and
The protein of the acidified milk modulation of acquisition, more preferably using passing throughLactobacillus bulgaricus (Lactobacillus bulgaricus)WithStreptococcus thermophilus (Streptococcus thermophilus)Combination make skim-milk fermentation and obtain
The protein of acidified milk modulation.
The quark of an embodiment as the acidified milk for obtaining the protein from acidified milk in the present invention
Such as it can manufacture by the following method.
By ox skimmed milk heat sterilize, then, will become fermentation leavening lactic acid bacteria (Lactobacillus bulgaricus (Lactobacillus bulgaricus)WithStreptococcus thermophilus (Streptococcus thermophilus)Mixture) with
Mode as 0.5~5% (W/W) is inoculated with and makes its fermentation.If reaching about 4.6 by the pH for the ox skimmed milk that ferments,
Ox skimmed milk is separated into curdled milk (curd) and whey.The curdled milk that sepg whey is obtained is cooling and obtains quark.It operates in this way
And obtain quark composition be, for example, all solids ingredient 17~19% (w/w), protein 11~13% (w/w), fat it is small
In 1% (w/w), carbohydrate 2~8% (w/w), lactose less than 2% (w/w).In addition, quark can also be become by inoculation
The lactic acid bacteria of leavening makes its fermentation, and addition rennet makes it solidify and obtain.In addition, as the lactic acid for becoming leavening
Bacterium, also can be used Lactococcus lactis (Lactococcus lactis) and/or butterfat galactococcus (Lactococcus cremoris) and Leuconostoc mesenteroides (Leuconostoc mesenteroides) etc. leukonids (Leuconostoc) belong to thin
The mixture of bacterium.
The content of the protein from acidified milk in composition of the invention can content, group according to other ingredients
It closes the morbid state for giving object of object, symptom, age, weight, purposes etc. and carrys out appropriate adjustment.Specifically, composition of the invention
In the protein from acidified milk content be every 100kcal composition be 0.5~6.0g, preferably 2.0~6.0g, more
Preferably 2.5~4.5g.It should be noted that adding about the protein from acidified milk of the invention to what composition added
Adding method, as long as not interfering effect of the invention, there is no particular limitation, can make directly to contain in composition with Yoghourt, overstate
Gram it is the above-mentioned acidified milk of representative, can also makes to contain the albumen from acidified milk isolated by acidified milk in composition
Matter.
Fat constituent
Fat constituent of the invention includes medium chain fatty acid or its triglycerides and n-3 system fatty acid.
As medium chain fatty acid of the invention, the preferably medium chain fatty acid of carbon atom number 8~14.In addition, of the invention
The preferred part of it of medium chain fatty acid or all with MCT Oil (MCT:Medium-chain
Triglyceride form) by comprising.MCT, which has, to be absorbed rapidly in vivo and is easy to become energy, and fat is not easy to adhere to
The feature as body.As the grease comprising MCT, palm oil, palm-kernel oil and coconut oil etc. can be enumerated and planted by Palmae
Grease, the grease containing medium chain fatty acid etc. that object obtains.Composition of the invention can directly comprising medium chain fatty acid or its
Triglycerides can also include in the form of above-mentioned grease.
As n-3 system fatty acid of the invention, can enumerate docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA),
Alpha-linolenic acid, clupanodonic acid (DPA) etc., preferably alpha-linolenic acid, DHA and EPA, more preferably DHA and EPA.As
Grease comprising n-3 system fatty acid can enumerate fish oil, perilla herb oil, Linseed oil (Flax Oil), weak siritch, rapeseed oil, big
Soya-bean oil and canola oil (salad oil) etc..Composition of the invention can directly include n-3 system fatty acid, can also be with above-mentioned grease
Form include.
In composition of the invention, other than medium chain fatty acid or its triglycerides and n-3 system fatty acid, it can also wrap
Containing other fatty acid.
As other fatty acid, oleic acid, palmitinic acid, palmitoleic acid, linoleic acid, stearic acid, linolenic acid and peanut can be enumerated
The n-6 such as tetraenoic acid etc., preferably linoleic acid system fatty acid.As the grease comprising other fatty acid, the height of high oleic acid can be enumerated
The edible oils such as oleic sunflower oil, rapeseed oil, olive oil, high oleic safflower oil, soybean oil, corn oil and palm oil.Of the invention
Composition can include directly other fatty acid, can also include in the form of above-mentioned grease.
Preferred embodiment according to the present invention, the weight of n-6 system fatty acid and n-3 system fatty acid in composition of the invention
Than being preferably 1~3, more preferably 1.5~2.5, further preferably 1.8~2.2, further preferably 1.9~2.1.
Composition of the invention may include one or more newborn phosphatide, the lecithin from soybean, egg yolk lecithins etc.
Well known phosphatide.Phosphatide of the invention can be separated by the raw material that cream, soybean, egg etc. become source, be refined.As long as in addition, can
Obtain effect of the invention, so that it may use commercially available phosphatide.
As phosphatide of the invention, preferably newborn phosphatide.Newborn phosphatide (also referred to as newborn lecithin) by sphingomyelin (SM),
Phosphatidyl choline (PC), phosphatidyl-ethanolamine (PE), phosphatidylinositols (PI), phosphatidylserine (PS), hemolytic phosphatidyl gallbladder
Alkali (LPC) is constituted, and is only locally present in butterfat ball film (MFGM).MFGM phospholipid composition is recorded in for example, dairy industry at being grouped as
Technology Bulletin of Japan Dairy Technical Association, Vol.50:pp.58-91,2000.
About the content of the phosphatide in composition of the invention, as long as not interfering effect of the invention, so that it may according to it
Content, the morbid state for giving object of composition, symptom, age, weight, purposes of its ingredient etc. carry out appropriate adjustment.Suitable phosphorus
The content of rouge is that every 100kcal composition is 1~15g, 1~10g, 2~10g, 3~10g, 4~10g, 5~10g, 6~10g, 7
~10g or 7~9g.
Carbohydrate content
Composition of the invention includes the isomaltoketose as carbohydrate content.Isomaltoketose is CAS Registry volume
Substance shown in number 13718-94-0, chemical formula C12H22O11.
Isomaltoketose is commercially available with palatinose (パ ラ チ ノ ー ス (registered trademark)), is included in commercially available para gold
In the products such as syrup, isomalt, palatinose malt sugar.In composition of the invention, isomaltoketose can be added
Itself, can also add the said products containing isomaltoketose.
In addition, composition of the invention may include the carbohydrate other than isomaltoketose.Other than isomaltoketose
Carbohydrate can enumerate sucrose, glucose, fructose, honey, dextrin etc..
The content of carbohydrate in composition of the invention can according to the contents of other ingredients, absorb morbid state, the disease of object
Shape, age, weight, purposes etc. carry out appropriate adjustment.The content of suitable carbohydrate be every 100kcal composition be 1~25g, 1~
22g, 2~20g, 4~18g, 4~16g, 6~16g, 6~16g, 8~14g, 10~14g, 1~15g, 1.5~12g, 2~10g,
3~9g, 4~8g or 5~7g.
In addition, in the present compositions, the weight rate of protein component and lipid components is preferably 0.3:1~3:
1, more preferably 1.4:1~2:1.
In addition, in the present compositions, the weight rate of protein component and carbohydrate content is preferably 1:2~1:
20, more preferably 1:2~1:4.
In addition, in the present compositions, the weight rate of lipid components and carbohydrate content is preferably 1:3~1:7, more
Preferably 1:4~1:6.
Additional nutritional ingredient
Composition of the invention can be by cooperating at least one kind of or combination to cooperate two or more additional nutrient, to adjust
Its nutrition composition, flavor, form, pH, osmotic pressure etc..As the additional nutrient in the present invention, as long as not interfering this hair
Bright effect, there is no particular limitation, amino acid, dietary fiber, vitamins, minerals class, organic acid, organic can be enumerated
Alkali, fruit juice, perfumery, artificial sweetening's (such as Aspartame etc.), moisture etc..
Dietary fiber is divided into water-soluble dietary fiber and insoluble diedairy fiber, can be used any number of in the two.Make
For water-soluble dietary fiber, can enumerate for example, indigestible oligosaccharides, indigestible dextrins, lactitol, gossypose, pectin, Guar
Glue etc..In addition, it is more that cellulose, hemicellulose, lignin, chitin, deacetylated shell can be enumerated as insoluble diedairy fiber
Sugar, soybean dietary fiber, wheat wheat bran, pina fibre (パ イ Application Off ァ イ バ ー), zein fiber, beet fiber etc..
The content of dietary fiber in composition of the invention is not particularly limited, can according to the contents of other ingredients,
Morbid state, symptom, age, weight, the purposes etc. of intake object carry out appropriate adjustment.The content of suitable dietary fiber is every
100kcal composition is 0.5~10g, 0.5~8g, 0.5~6g, 0.5~4g, 0.5~2g or 1~2g.
As the suitable examples of vitamins, vitamin A, vitamin B1, vitamin B2, vitamin B6, vitamin can be enumerated
B12, vitamin C, vitamin D, vitamin E, vitamin K, niacin, folic acid, biotin, pantothenic acid or they part or all
Combination etc., but more preferably biotin.
The content of vitamins in composition of the invention can according to the contents of other ingredients, absorb the disease of object
State, symptom, age, weight, purposes etc. carry out appropriate adjustment.The content of suitable vitamin ingredients is that every 100kcal composition is 1
~200 μ g, 10~200 μ g, 20~100 μ g, 30~100 μ g, 40~100 μ g or 40~60 μ g.In addition, suitable biotin
Content is that every 100kcal composition is 0.5~20 μ g, 0.5~10 μ g, 1~10 μ g, 2~10 μ g, 4~10 μ g, 5~9 μ g, 6.5
~8 μ g or 7~8 μ g.
As the suitable examples of minerals class, can enumerate sodium, chlorine, potassium, sulphur, magnesium, calcium, phosphorus, iron, iodine, manganese, copper, zinc, selenium, chromium,
Molybdenum or their some or all of combination etc., but more preferably sodium, zinc or copper or their combination.
The content of minerals class in composition of the invention can according to the contents of other ingredients, absorb the disease of object
State, symptom, age, weight, purposes etc. carry out appropriate adjustment.The content of suitable minerals class is that every 100kcal composition is 10
~900mg, 30~800mg, 40~700mg, 100~600mg, 150~550mg, 200~500mg, 250~500mg or 300
~500mg.In addition, the content of suitable sodium be every 100kcal composition be 10~150mg, 20~130mg, 30~110mg,
40~100mg, 50~90mg, 60~80mg or 65~75mg.In addition, the content of suitable zinc is that every 100kcal composition is
0.01~30mg, 0.05~15mg, 0.05~10mg, 0.1~7mg, 0.3~5mg, 0.5~2.5mg or 0.5~1.5mg.This
Outside, it is 0.002~20mg, 0.004~15mg, 0.006~10mg, 0.008 that the content of suitable copper, which is every 100kcal composition,
~5mg, 0.01~1mg or 0.03~0.07mg.
In addition, it is 1~99g, 10~99g, 30 that the content of the moisture in composition of the invention, which is every 100kcal composition,
~99g, 50~99g, 70~99g, 75~99g, 80~99g or 80~90g.
About the form of composition of the invention, as long as not interfering effect of the invention, there is no particular limitation, Ke Yiwei
Liquid, paste, solid, powder etc., but preferably liquid.
The pH of composition of the invention is not particularly limited, for example, its pH can be pH2~pH6, preferably pH3~
pH5。
The osmotic pressure of composition of the invention is not particularly limited, for example, about 300~1000mOsm/L, preferably from about
300~750mOsm/L.
In addition, the viscosity of composition of the invention is, for example, about 5~100cp (1cp=in the case where measuring at room temperature
0.001Pas), preferably less than 80.
In addition, the calorie of composition of the invention is not particularly limited, for example, about 0.5~2kcal/mL, preferably 1
~1.5kcal/mL.
The modulator approach of composition of the invention is not particularly limited, can by known method, by mentioned component cooperation,
It homogenizes and implements.In addition, preferably being killed to well known to composition of the invention or the implementation of each ingredient in modulator approach of the invention
Bacterium (heating etc.) processing.Therefore, according to the solution of the present invention, the caused nerve ending given by anticarcinogen is provided
Improve the manufacturing method for using composition, it includes following processes: will be as the milk protein hydrolysate of protein component and source
In the protein of acidified milk；As the medium chain fatty acid of fat constituent or its triglycerides and n-3 system fatty acid；And as sugar
The process of the isomaltoketose cooperation of constituents in the composition, and composition is homogenized and heated as needed
Process.Sterilization process and the number for the process that homogenizes are not particularly limited, and can carry out as described later repeatedly.Mixed processes,
The process that homogenizes and the sequence of sterilization process are not particularly limited, and the process that homogenizes is carried out preferably after sterilization process.In addition,
In the case where the use form of composition is powder, homogeneous compound can be for example spray-dried, be freeze-dried.
Hereinafter, enumerating more specific example about modulator approach of the invention and being illustrated.
Firstly, in advance stirring warm water in tank in the preference of modulator approach of the invention, consider that mixing, diffusion are held
Easy property and successively add, mix thereto, the ingredient other than stirring vitamins, mixed liquor is made.Raw material is set to be easily mixed, expand
Scattered ordering in launching difference according to amount, the characteristic of raw material, it is primary or separate and put into various orders, such as have according to carbohydrate,
Protein, fat, minerals class sequence investment method.Furthermore as another example, there are the carbohydrate according to a part, egg
White matter, other carbohydrates, minerals class, the method for the sequence investment of fat.Be further used as another example, have according to fat,
Protein, carbohydrate, minerals class sequence investment method.By the mixed liquor with steam-sprayed heating sterilization after, with equal
Matter machine is homogenized and (is homogenized with the pressure of two-stage), and the liquid that homogenizes is made.To homogenize the liquid addition, mixed vitamin
Class, fragrance (flavor) etc., are made final mixed liquor.The final mixed liquor can further be carried out with steam injection type
After heating sterilization (two-stage sterilization), is homogenized and (homogenized with the pressure of two-stage) with homogenizer and obtain combination of the invention
Object.
Mixing condition in modulator approach of the invention can according to the type of ingredient and composition, ratio, property etc. come
It suitably sets, mixing temperature when protein is mixed is, for example, 2 DEG C~70 DEG C, preferably 55 DEG C hereinafter, more preferably 5~55
DEG C, further preferably 40~55 DEG C, further preferably 40~53 DEG C, further preferably 40~50 DEG C.Use albumen
The range that mixing temperature when matter is 2 DEG C~70 DEG C, in the solidification (rennet) for preventing protein, also, makes protein to water
It is preferred Deng dissolution or dispersion aspect.
In addition, well known high-temperature sterilization treatment is preferably implemented in sterilization process of the invention.In sterilization process, for example, can
So that temperature is 100~150 DEG C, make the retention time 1~30 second, preferably 115~145 DEG C, 1~20 second, more preferably 120
~145 DEG C, 1~10 second, further preferably 125~140 DEG C, 1~5 second.
In addition, pressure (pressurization, decompression) can be adjusted to mixed liquor when carrying out high temperature sterilization.At this point, being typically based on anti-
The purpose of only mixed liquor boils, for example, making 1~10kg/cm of sterilization pressure2Left and right.That is, being removed in high temperature sterilization of the invention
Other than temperature (heating), such pressure can also be applied.Moreover, having as the device for carrying out high temperature sterilization for example, board-like
Heat exchanger, tubing heat exchanger, steam-sprayed sterilization machine, steam injection type sterilization machine, electrified regulation formula sterilization machine etc..
In addition, preferably after sterilizing mixed liquor, homogenizing in the present invention.It homogenizes and is dropping after sterilization
It is preferred in terms of the low thickening degree with heating when sterilizing.It here, can be with as the number to homogenize after sterilization
For 1 time or repeatedly.For example, after having carried out to mixed liquor the 1st sterilization in the case where the 2nd sterilization of further progress,
Homogenize for the 1st time after the 2nd sterilization.In addition, homogenizing after carrying out the 1st sterilization to mixed liquor, into one
In the case that step carries out the 2nd sterilization, homogenize for the 2nd time after the 2nd sterilization.In addition, by mixed liquor
It homogenizes after sterilization, in the case where sterilizing without the 2nd time, can directly carry out homogenizing for the 2nd time.
The process that homogenizes can be used well known homogenizer and implement.About the suitable condition for the process that homogenizes, as long as not
Interfere effect of the invention, there is no particular limitation, for example, being by flow set temperature is set as 10~60 DEG C or so
In the case where 100~10000L/h or so, make 10~100MPa of pressure, preferably 20~80MPa, more preferably 30~
70MPa, further preferably 20~50MPa.
It should be noted that can also will homogenize to before vessel filling or after filling in modulator approach of the invention
Object (homogenize by bactericidal liquid and obtain) is sterilized again.Specifically, can be using as needed again by homogeneous
Compound has carried out carrying out the method for aseptic filling (for example, UHT bactericidal assay is used in combination with aseptic packaging processes after cooling after heating is sterilized
Method), to can container or flexible package filling after cooking disinfection method (for example, cooking process, autoclave method).
In addition, as described above operate and obtain composition of the invention can be used as needed it is pharmaceutically acceptable
Additive it is further formulation, the present invention in also include such scheme.As pharmaceutically acceptable additive, can enumerate
Excipient, adhesive, disintegrating agent, lubricant, flavoring agent, cosolvent, suspending agent, coating agent, solvent, isotonic agent etc..
Composition of the invention is with drug, diet product, alimentation composition, dietary supplement, particular utility food, nutrition
Functional food, healthy food, drug additive, functional display any form such as food or food additives can be suitble to benefit
With.
According to the present invention, by making object absorb above-mentioned composition, it can effectively improve and be drawn by giving for anticarcinogen
The nerve ending risen.Therefore, other schemes according to the present invention, provide a kind of method, are drawn by giving for anticarcinogen
The ameliorative way of the nerve ending risen, it includes following step: the object for having the needs being made to absorb a effective amount of present invention
Composition.Here, so-called " improvement " of the invention, not only comprising being treated to the morbid state or symptom established, but also
It include to prevent the morbid state or symptom with a possibility that being established in the future.
So-called " object " of the invention, is not particularly limited, preferably mammal, is more preferably people, livestock animals kind
Or wild animal etc., it is further preferably people, is further preferably people's cancer patient.
In addition, occurring nerve ending as long as possible as anticarcinogen of the invention, there is no particular limitation, can be with
Using well known anticarcinogen, can enumerate for example, for leukaemia, malignant lymphoma, myeloma, lung cancer, breast cancer, colorectal cancer, liver
The anticarcinogen of cell cancer, Gastrointestinal Stromal Tumor, clear-cell carcinoma etc..More specifically, it as anticarcinogen of the invention, can enumerate pair
Micro-pipe damages and causes the anticarcinogen of nerve ending.As the suitable examples of such drug, taxol, more can be enumerated
The vinca alkaloids system drugs such as the Japanese yews such as Xi Tasai system drug, vincristine, vincaleukoblastinum, eldisine, vinorelbine.This
Outside, the anticarcinogen for causing neural axon obstacle so as to cause nerve ending due to the injury because of nerve cell can be enumerated.
As the suitable examples of such drug, the platinum preparation such as oxaliplatin, carboplatin, cis-platinum, Nedaplatin can be enumerated.
As the suitable examples of the nerve ending as caused by anticarcinogen, shouting pain can be enumerated, burn the pains such as such pain
Bitterly, the abnormal perceptions such as numbness, burning heat sensation of limb end, hypergnosias, the anesthesia such as allergy/feeling fiber crops to creeping chill stimulation
The cacesthesias such as numbness, uncoordinated, aesthesia ataxia, reduction of muscle strength etc..The end as caused by anticarcinogen of the invention
Tip neurological disorder is embodied not only in the nerve ending generated in the single agenttherapy for having used a kind of anticarcinogen, and includes
In the multi-agent conjoint therapy for giving the different a variety of pharmaceutical compositions of the mechanism of action, in order to which the drug for keeping the mechanism of action different can be with
The biochemical adjusting (biochemical modulation) for playing maximum validity and working hard the combination of drug, administration way
Therapy in the nerve ending that generates.
Allow object absorb composition of the invention method be it is oral or para-oral any, intake form can
The form for thinking drug may be the form of the non-drugs such as diet product.
In the case where making composition of the invention as drug intake, it can be cited for example that, enteric nutrient, liquor etc.
Given through nasal tube, using the enteral or orally administration of gastric fistula, intestinal fistula etc., or be processed into tablet, capsule, particle
The preparations such as agent, powder, syrup give form.
In addition, may be exemplified cow's milk, cold drink in the case where absorbing composition of the invention as diet product
(fruit juices type beverage, cream stir type beverage etc.), acidified milk, Yoghourt, cheese, bread, biscuit, crispbread, Pizza cake skin,
Modulate powder cream, liquid food, patient's food, nutraceutical, frozen food, food compositions, processed food and other commercially available foods
The forms such as product.In addition, composition may be the soluble powder that can be reconstructed before use.
About the period for absorbing composition of the invention, as long as not interfering effect of the invention, there is no particular limitation, this
The composition of invention absorbs preferably before giving anticarcinogen, during giving anticarcinogen and/or after giving anticarcinogen.In addition, this
The composition of invention can before meals, after meal, suitably absorb between meal and/or before sleeping.In addition, composition of the invention can also generation
It is used for food, can also be used as the auxiliary of food and utilize.
The effective quantity of composition of the invention can suitably be adjusted according to the gender of object, symptom, state, weight etc.,
It is 10~3000kcal, 50~2500kcal, 50~2000kcal, 100 each day that suitable effective quantity, which is converted into calorie to be,
~2000kcal, 100~1500kcal, 100~1250kcal, 100~1000kcal, 150~850kcal, 150~
650kcal or 200~600kcal.In addition, it is every that the suitable effective quantity of composition of the invention, which is converted into solids by weight,
One day for 2~665g, 11~555g, 11~445g, 22~445g, 22~335g, 22~280g, 22~280g, 33~190g,
33~145g or 45~135g.In addition, the suitable effective quantity of composition of the invention be converted into solids by weight can be
Each each patient is suitably adjusted in the range of being 0.5~135g.In addition, composition of the invention can be with 1 day 1~3 time or so
Intake 1 week or more (preferably 1 month~12 months or so).
In addition, other schemes according to the present invention, provide composition in improvement and give caused tip by anticarcinogen
Application in neurological disorder, above-mentioned composition include: as the milk protein hydrolysate of protein component and from acidified milk
Protein；As the medium chain fatty acid of fat constituent or its triglycerides and n-3 system fatty acid；And as carbohydrate content
Isomaltoketose.In addition, further other schemes according to the present invention, composition is provided caused by giving for anticarcinogen
Application in the manufacture of the improvement composition of nerve ending, above-mentioned composition includes: the newborn egg as protein component
White matter hydrolysate and protein from acidified milk；As the medium chain fatty acid of fat constituent or its triglycerides and n-3 system
Fatty acid；And the isomaltoketose as carbohydrate content.In addition, further other schemes according to the present invention, provide and are used for
Improve and gives caused nerve ending, milk protein hydrolysate as protein component and source by anticarcinogen
In the protein of acidified milk；As the medium chain fatty acid of fat constituent or its triglycerides and n-3 system fatty acid；And as sugar
The combination of the isomaltoketose of constituents.Above scheme can be implemented based on the record of the compositions and methods of the invention.
Embodiment
Hereinafter, enumerate embodiment illustrates the present invention in further detail, but the present invention is not limited thereto.It needs to illustrate
It is that % is recorded as long as no special in the examples below, means that weight %.In addition, the unit and survey of present specification
Method is determined, according to the regulation of Japanese Industrial Specifications (JIS) if without particularly recording.
Embodiment 1: the modulation for trying composition
Milk protein hydrolysate
By as the whey protein sepd of about 90% protein content of dried object (WPI, ダ ビ ス U society), with
The protein content of 8% (w/v) is dissolved in distilled water.Solution heats 2 minutes at 85 DEG C makes protein denaturation.The heating
The pH of solution afterwards is about 7.5.Hydrolysis is to add ア Le カ ラ ー ゼ 2.4L (enzyme, ノ ボ relative to substrate with 2.0% concentration
ザ イ system ス society) and reacted 3 hours at 55 DEG C.Next, relative to substrate using 3.0% concentration addition as pig source
The PTN 6.0S (ノ ボ ザ イ system ズ ジ ャ パ Application) of trypsase simultaneously reacts 3 hours at 55 DEG C.Total hydrolysis time is 6 small
When.PH at the end of reaction is about 7.0.Resulting reaction solution is subjected to centrifugal treating (20,000 × g, 10 minutes), further
The UF film process (ミ リ Port ア society ウ Le ト ラ フ リ ー-MC) for carrying out molecular cut off 10,000, obtains milk protein hydrolysate
(serum protein hydrolysate).
From the protein of acidified milk
After skimmed milk is sterilized (120 DEG C, 30 seconds), with leavening (Bulgaria of 5% left and right (w/w) inoculating lactic acid bacterium
Lactobacillus (Lactobacillus bulgaricus) and streptococcus thermophilus (Streptococcus thermophilus)) and
Make its fermentation.The pH of resulting fermentation liquid reaches about 4.6, after forming curdled milk, is centrifugated whey using separator, by gained
Curdled milk it is cooling, obtain the protein from acidified milk.
For trying composition
It is assumed that obtaining for trying composition 100L, 55 DEG C of warm water is stirred in tank in advance, addition protein component (contains
Milk protein hydrolysate 2kg, from the protein 3kg of acidified milk), fat constituent (contain MCT Oil
0.59kg, refined fish oil 0.2kg, edible oil 1.91kg) and sugared ingredient (containing isomaltoketose 7kg), dietary fiber 1.2kg,
Minerals class 71g (contains sodium, zinc, copper), is mixed.Resulting mixed liquor is subjected to heating sterilization (135 with steam-sprayed
DEG C, 5 seconds) after, it is homogenized (15MPa) with homogenizer, the liquid that homogenizes is made.To the liquid addition that homogenizes, mixed biologic element
7.5mg etc., obtains mixed liquor again.Resulting mixed liquor is adjusted to pH3.8 with citric acid, further with steam injection type
After heating sterilization (135 DEG C, 5 seconds), is homogenized (15MPa) with homogenizer and obtain and supplied shown in Tables 1 and 2 below
Try composition (100kcal/100mL) 100L.It should be noted that for docosahexaenoic acid and 20 carbon in examination composition
The content of five olefin(e) acid adds up to 0.06g, for the weight ratio (n-6/ of n-6 system fatty acid and n-3 system fatty acid in examination composition
It n-3) is 2.0.Above-mentioned n-6 system fatty acid is linoleic acid, and n-3 system fatty acid is alpha-linolenic acid, docosahexaenoic acid and 20
The mixture of carbon 5 alkene acid.
[table 1]
[table 2]
Embodiment 2: the validation test of the improvement of the nerve ending as caused by anticarcinogen
During chemotherapy is implemented, selection can arrive cancer patient 2 that hospital outpatient sees a doctor and can continue to research in itself
(case 1- women, 43 years old, Malignant Lymphoma, the IV phase；Case 2- women, 47 years old, PATIENTS WITH LARGE BOWEL, IV phase) as tested
Person.Chemotherapy is will to be used as 1 period within about 20 days, and give anticarcinogen drop to subject within first day in each period.
It should be noted that it is that, for Malignant Lymphoma, preceding 2 anticarcinogens make when giving that anticarcinogen, which gives scheme,
With R-CHOP therapy (Rituximab 520mg, cyclophosphamide 1040mg, adriamycin 69mg, vincristine 1.9mg), latter 2 times
R-CVP therapy (Rituximab 520mg, cyclophosphamide 1040mg, vincristine 1.9mg) has been used when anticarcinogen is given.
In addition, 4 times initial anticarcinogens have used CapeOX therapy (capecitabine when giving for PATIENTS WITH LARGE BOWEL
1200mg, oxaliplatin (L-OHP100mg), last 1 anticarcinogen have used (the card training of R-CVP Cape/Bev therapy when giving
He is shore 1200mg, Avastin 270mg).
In addition, setting absorbs the A course for the treatment of for trying composition and only absorbs the B treatment of usual food in chemotherapy implementation
Journey carries out each course for the treatment of of A, B to each subject's alternate repetition.Specifically, chemically therapy implements (drop to subject in the A course for the treatment of
Treatment is implemented) before 3 days to the previous day is implemented with 1 day 3 (being equivalent to 600kcal) oral uptake for examination composition, further from
It was then orally taken the photograph by this 4 days the 3rd day after chemotherapy with 1 day 1 (being equivalent to 200kcal) oral uptake on the day of chemotherapy
Take food as usual.On the other hand, in the case where the B course for the treatment of, subject chemotherapeutic front and back as usual
Oral uptake food.
In test, subject is to adjoint chemotherapeutic nerve ending (numb etc.), with Common
The adverse events of the version 4 of Terminology Criteria for Adverse Events (CTCAE) are used as reference,
4 grades of evaluations are implemented by oneself record of sufferers themselves.The classification of evaluation is by Grade0 to be set as that normally, Grade1 being set
To there is slight numb, pain, life is not caused although Grade2 is set as the handicapped sense as caused by numb, pain
Puzzlement, by Grade3 is set as numb, pain seriously perplexs life.
As a result as illustrated in figures 1 and 2.About the nerve ending of the side effect as anticarcinogen, usually every time
It can all be accumulated by chemotherapy, the Grade of the adverse events of nerve ending will not decline.However, the knot of this test
Fruit is that any subject when intake is for examination composition, confirms the drop of the Grade of the adverse events of nerve ending
It is low.Specifically, in the Malignant Lymphoma of Fig. 1, by and with for trying composition, in the drop the (the 60th of the 3rd anticarcinogen
It) when adverse events from Grade2 be reduced to Grade1.In addition, in the PATIENTS WITH LARGE BOWEL of Fig. 2, if to until the 60th day
Period is observed, then does not absorb for examination composition and in the case that anticarcinogen is carried out drop (the 25th day), adverse events
Rising be from Grade0 to Grade2, in contrast, and with for try composition intake and by anticarcinogen carry out drop (the 4th day,
46th day) in the case where, the rising of adverse events is suppressed to from Grade0 to Grade1.
In addition, any subject is difficult to absorb without the decline because of appetite to hinder for trying composition in nerve ending
While the improvement hindered, nutrient is persistently carried out using for examination composition.
Claims (17)
1. a kind of composition gives caused nerve ending by anticarcinogen for improving, it includes: as protein
The milk protein hydrolysate of ingredient and protein from acidified milk；As the medium chain fatty acid of fat constituent or its glycerol three
Ester and n-3 system fatty acid；And the isomaltoketose as carbohydrate content.
2. composition according to claim 1, the lactoprotein be selected from casein, lactoprotein concentrate (MPC),
In whey protein concentrate (WPC), whey protein sepd (WPI), α-lactalbumin, beta lactoglobulin and lactoferrin
It is at least one kind of.
3. composition according to claim 1 or 2, the milk protein hydrolysate is serum protein hydrolysate.
4. composition described in any one of claim 1 to 3, the content of the milk protein hydrolysate is every
100kcal composition is 0.5~3g.
5. composition according to any one of claims 1 to 4, the protein source from acidified milk is in fresh
Cheese.
6. composition according to any one of claims 1 to 5, the protein from acidified milk is to be added using guarantor
Leah lactobacillus (Lactobacillus bulgaricus), streptococcus thermophilus (Streptococcus thermophilus) or
Their combination makes skim-milk fermentation and the protein of acidified milk that obtains.
7. the content of composition described according to claim 1~any one of 6, the protein from acidified milk is every
100kcal composition is 0.5~6g.
8. composition according to any one of claims 1 to 7, the medium chain fatty acid is in carbon atom number 8~14
Chain fatty acid.
9. the content of composition described according to claim 1~any one of 8, the medium chain fatty acid or its triglycerides is
Every 100kcal composition is 0.01~2g.
10. composition described according to claim 1~any one of 9, n-3 system fatty acid includes to be selected from 22 carbon six
One or more of olefin(e) acid and eicosapentaenoic acid fatty acid.
11. composition described according to claim 1~any one of 10, the content of n-3 system fatty acid is every 100kcal
Composition is 0.05~2.2g.
12. composition described according to claim 1~any one of 11, the content of the isomaltoketose is every 100kcal
Composition is 1~15g.
13. composition described according to claim 1~any one of 12 further comprises as the n-6 system of lipid components
The weight ratio of fatty acid, the n-6 system fatty acid and n-3 system fatty acid is 1~3.
14. composition described according to claim 1~any one of 13 is further included selected from dietary fiber, vitamin
At least one kind of ingredient in class and minerals class.
15. composition described according to claim 1~any one of 14 is beverage or liquid food.
16. a kind of method is the method for giving caused nerve ending improved by anticarcinogen, it includes following steps
It is rapid: to make to need to be improved and a effective amount of combination of the invention is absorbed by the object for giving caused nerve ending of anticarcinogen
Object.
17. composition is for improving answering in the manufacture by the composition for giving caused nerve ending of anticarcinogen
With the composition includes: the milk protein hydrolysate as protein component and the protein from acidified milk；As rouge
The medium chain fatty acid of fat ingredient or its triglycerides and n-3 system fatty acid；And the isomaltoketose as carbohydrate content.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2016161457A JP6325036B2 (en) | 2016-08-19 | 2016-08-19 | Composition for improving peripheral neuropathy caused by anticancer agent |
| JP2016-161457 | 2016-08-19 | ||
| PCT/JP2017/029647 WO2018034345A1 (en) | 2016-08-19 | 2017-08-18 | Composition for improving peripheral neuropathy caused by anticancer agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109641027A true CN109641027A (en) | 2019-04-16 |
Family
ID=61196731
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201780050200.XA Pending CN109641027A (en) | 2016-08-19 | 2017-08-18 | For improving the composition of the nerve ending as caused by anticarcinogen |
Country Status (5)
| Country | Link |
|---|---|
| JP (1) | JP6325036B2 (en) |
| CN (1) | CN109641027A (en) |
| SG (1) | SG11201900960WA (en) |
| TW (1) | TWI754662B (en) |
| WO (1) | WO2018034345A1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI802808B (en) * | 2019-07-24 | 2023-05-21 | 生展生物科技股份有限公司 | Use of streptococcus thermophilus strain st4 as an auxiliarie of a chemotherapeutic agent for improving diarrhea, depraved appetite, and weight maintenance |
| WO2023053828A1 (en) * | 2021-09-30 | 2023-04-06 | テルモ株式会社 | Chemotherapy control device, chemotherapy control system, method for controlling chemotherapy control device, and chemotherapy control program |
| JP7323688B1 (en) | 2022-08-25 | 2023-08-08 | 盈太企業股▲ふん▼有限公司 | folding storage device |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1741749A (en) * | 2002-11-22 | 2006-03-01 | 明治乳业株式会社 | Nutritional compositions |
| CN101790377A (en) * | 2007-08-31 | 2010-07-28 | 国立大学法人九州大学 | Prophylactic or alleviating agent for peripheral nerve disorder induced by anti-cancer agent |
| CN102665750A (en) * | 2009-11-30 | 2012-09-12 | 株式会社明治 | Nutritional composition beneficial to small intestine |
| CN103561756A (en) * | 2011-05-27 | 2014-02-05 | 株式会社明治 | Composition for preventing and/or ameliorating cancer-related irreversible metabolism disorders |
| CN103957720A (en) * | 2011-11-30 | 2014-07-30 | 株式会社明治 | Nutritional composition for improving intestinal flora |
| CN104394885A (en) * | 2012-05-31 | 2015-03-04 | 学校法人近畿大学 | Agent for preventing and/or treating peripheral neuropathic pain caused by anti-cancer drug |
| CN105705037A (en) * | 2013-07-31 | 2016-06-22 | 株式会社明治 | Nutritional composition for inhibiting growth of tumor |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6775419B2 (en) * | 2014-04-22 | 2020-10-28 | 味の素株式会社 | Composition for prevention or improvement of peripheral neuropathy |
| JP6657084B2 (en) * | 2014-06-25 | 2020-03-04 | 株式会社明治 | Ghrelin secretagogue |
-
2016
- 2016-08-19 JP JP2016161457A patent/JP6325036B2/en active Active
-
2017
- 2017-08-18 TW TW106128042A patent/TWI754662B/en active
- 2017-08-18 WO PCT/JP2017/029647 patent/WO2018034345A1/en active Application Filing
- 2017-08-18 SG SG11201900960WA patent/SG11201900960WA/en unknown
- 2017-08-18 CN CN201780050200.XA patent/CN109641027A/en active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1741749A (en) * | 2002-11-22 | 2006-03-01 | 明治乳业株式会社 | Nutritional compositions |
| CN101790377A (en) * | 2007-08-31 | 2010-07-28 | 国立大学法人九州大学 | Prophylactic or alleviating agent for peripheral nerve disorder induced by anti-cancer agent |
| CN102665750A (en) * | 2009-11-30 | 2012-09-12 | 株式会社明治 | Nutritional composition beneficial to small intestine |
| CN103561756A (en) * | 2011-05-27 | 2014-02-05 | 株式会社明治 | Composition for preventing and/or ameliorating cancer-related irreversible metabolism disorders |
| CN103957720A (en) * | 2011-11-30 | 2014-07-30 | 株式会社明治 | Nutritional composition for improving intestinal flora |
| CN104394885A (en) * | 2012-05-31 | 2015-03-04 | 学校法人近畿大学 | Agent for preventing and/or treating peripheral neuropathic pain caused by anti-cancer drug |
| CN105705037A (en) * | 2013-07-31 | 2016-06-22 | 株式会社明治 | Nutritional composition for inhibiting growth of tumor |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018034345A1 (en) | 2018-02-22 |
| JP6325036B2 (en) | 2018-05-16 |
| TW201817442A (en) | 2018-05-16 |
| SG11201900960WA (en) | 2019-03-28 |
| JP2018027925A (en) | 2018-02-22 |
| TWI754662B (en) | 2022-02-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103957720B (en) | Improving intestinal flora alimentation composition | |
| CN102665750B (en) | The alimentation composition beneficial to small intestine | |
| TWI722992B (en) | Brain function improving agent, and preventive or therapeutic agent for cognitive dysfunction | |
| CN105705037A (en) | Nutritional composition for inhibiting growth of tumor | |
| CN107252090A (en) | Purposes of the alimentation composition comprising lactoferrin in immunocyte is stimulated | |
| CN109641027A (en) | For improving the composition of the nerve ending as caused by anticarcinogen | |
| CN107668721A (en) | Purposes of the alimentation composition comprising lactoferrin in resist the disease and situation is supported | |
| RU2335132C1 (en) | Composition for production of functional milk product and method of functional milk product production | |
| TWI629992B (en) | Compositions for prevention and/or improvement of irreversible metabolic defect accompanying cancer | |
| Navamniraj et al. | Beneficial impacts of goat milk on the nutritional status and general well-being of human beings: anecdotal evidence. | |
| JP6037595B2 (en) | Satiety induction composition and method for producing the same | |
| JP2001097883A (en) | Aloe-containing nutritive composition | |
| CN105960244A (en) | Antibacterial peptide-inducing agent | |
| JP7025112B2 (en) | BDNF production promoter | |
| JP7263426B2 (en) | obesity inhibitor | |
| JP2006273744A (en) | Hypotensive material, its manufacturing method, food composition and pharmaceutical composition having hypotensive action | |
| JP7383874B2 (en) | Composition for inhibiting endotoxin transfer into blood | |
| RU2341276C1 (en) | Method of gastrointestinal disturbance prevention in newborn calfs | |
| TW201822640A (en) | Compositions comprising maltotriose and methods of using same to inhibit damage caused by dehydration processes | |
| Muthusamy | Milk Fat Globular Membrane: Composition, Structure, Isolation, Technological Significance and Health Benefits | |
| CN107105688A (en) | Phosphorus absorbs suppression composition | |
| WO2018074415A1 (en) | Composition for improving protein efficiency ratio | |
| Sahoo | Preserving its Therapeutic Potential | |
| JPH1146720A (en) | Nutritive composition for promoting absorption of calcium | |
| JP2021010374A (en) | Bdnf production promoting agent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40006523 Country of ref document: HK |
|
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190416 |
|
| RJ01 | Rejection of invention patent application after publication |